⚠ Evidence warning: Clinical trials or other evidence do not support the claims that D-phenylalanine lifts mood without tolerance or dependence, that cofactors determine whether the supplement works, and that particular types of depression respond best to phenylalanine. This page keeps it as a report of what people, websites or other media say.
Phenylalanine for Mood and Depression
Phenylalanine is the single dietary amino acid that sits at the head of the catecholamine cascade: it is hydroxylated to tyrosine, then to L-DOPA, and then in two further steps to dopamine, norepinephrine, and epinephrine. Because nearly every modern antidepressant ultimately tries to increase monoamine signaling, supplying the upstream precursor instead of blocking reuptake is one of the most mechanistically direct nutritional interventions for low mood. The L-form supports catecholamine synthesis; the D-form prolongs endogenous opioid signaling at the enkephalin receptor; the racemic DL-phenylalanine (DLPA) combines both. Small open studies from 1975 to 1986 (Fischer and Heller 1975, Beckmann 1977, Sabelli 1986) reported mood improvement in most patients given phenylalanine, but none had a placebo group; in the one double-blind trial (Beckmann 1979), DL-phenylalanine and the antidepressant imipramine did not differ on depression scores after 30 days — with the caveat that the response window is narrow and that tyrosine, one step further down the pathway, is an alternative precursor.
Table of Contents
- The Precursor Rationale for Mood
- The Phenylalanine to Catecholamine Pathway
- L-Phenylalanine vs D-Phenylalanine vs DLPA
- The First Open Studies (1975, 1977)
- The Sabelli Trials (1986, 1996)
- Beckmann and the European Trials
- Phenylalanine vs Tyrosine for Depression
- The Enkephalin / Endorphin Contribution to Mood
- Dosing, Timing, and Cofactors
- Cautions and Contraindications (Including PKU)
- Who Tends to Respond Best
- Key Research Papers
- Connections
- Featured Videos
The Precursor Rationale for Mood
The dominant pharmacologic theory of depression for the past sixty years has been the monoamine hypothesis: depressed patients have reduced synaptic availability of serotonin, norepinephrine, and dopamine, and treatments work by restoring monoamine signaling. Selective serotonin reuptake inhibitors (SSRIs) block serotonin reuptake, serotonin-norepinephrine reuptake inhibitors (SNRIs) block both serotonin and norepinephrine reuptake, bupropion blocks dopamine and norepinephrine reuptake, monoamine oxidase inhibitors (MAOIs) block monoamine catabolism, and so on. Every one of these drug classes acts downstream of synthesis — they redistribute or preserve what the neuron has already made.
The precursor-loading approach inverts this logic. Instead of preventing the loss of synthesized neurotransmitter, it supplies more raw material upstream so the neuron can simply make more. For the serotonin pathway, the precursor is tryptophan (or 5-HTP, one step closer to serotonin). For the catecholamine pathway — dopamine, norepinephrine, and epinephrine — the precursor is phenylalanine, which is hydroxylated to tyrosine, which is then hydroxylated to L-DOPA, which is decarboxylated to dopamine.
The biochemical question is whether the rate-limiting step in catecholamine synthesis is precursor availability or enzymatic capacity. For tyrosine hydroxylase — the conversion of tyrosine to L-DOPA — the enzyme is approximately 75 percent saturated at normal physiologic tyrosine concentrations, which means that increasing precursor supply can drive measurable increases in product. This is the biochemical foothold for the entire precursor-loading approach to mood. It also predicts a ceiling: at high enough tyrosine concentrations, the enzyme saturates and further supplementation does nothing additional. The dose-response curve for phenylalanine (or tyrosine) and mood is therefore expected to be flat at the low end (no benefit until you correct deficiency), steep in the middle (a meaningful improvement window), and flat again at the high end (you have saturated the enzyme).
The Phenylalanine to Catecholamine Pathway
The full catecholamine synthesis cascade has five enzymatic steps, three cofactor requirements, and one critical branch point. Understanding the cascade is essential for understanding why some patients respond dramatically to phenylalanine while others do not respond at all.
- Phenylalanine to tyrosine — performed by phenylalanine hydroxylase (PAH), a hepatic enzyme that requires tetrahydrobiopterin (BH4) as cofactor and oxygen as substrate. This is the step that is completely absent in classical phenylketonuria.
- Tyrosine to L-DOPA — performed by tyrosine hydroxylase (TH), the rate-limiting enzyme of the entire pathway. TH is found in catecholamine-producing neurons and adrenal chromaffin cells. It requires BH4 (the same cofactor used by PAH), iron (as a non-heme iron center in the active site), and oxygen.
- L-DOPA to dopamine — performed by aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase), which requires pyridoxal-5-phosphate (the active form of vitamin B6) as cofactor.
- Dopamine to norepinephrine — performed by dopamine beta-hydroxylase (DBH) inside catecholamine storage vesicles. DBH requires copper at the active site, ascorbate (vitamin C) as electron donor, and oxygen.
- Norepinephrine to epinephrine — performed by phenylethanolamine N-methyltransferase (PNMT), which is largely restricted to the adrenal medulla. PNMT requires S-adenosylmethionine (SAMe) as the methyl donor.
For depression specifically, the most relevant products are dopamine (motivation, anhedonia, reward) and norepinephrine (alertness, attention, energy). Epinephrine is mostly an adrenal hormone with relatively less central nervous system role.
The branch-point that matters clinically: at the dopamine to norepinephrine step, DBH requires copper. Patients with low copper status (which can result from zinc over-supplementation, ceruloplasmin deficiency, or severe nutrient deficiency) accumulate dopamine but produce less norepinephrine. Conversely, patients with adequate copper but low BH4 (which can result from methylenetetrahydrofolate reductase-related folate cycle dysfunction or genetic GTP cyclohydrolase I (GTPCH) deficiency) cannot push tyrosine to L-DOPA effectively no matter how much phenylalanine they take. The cofactor terrain matters as much as the precursor supply.
L-Phenylalanine vs D-Phenylalanine vs DLPA
Phenylalanine exists as two enantiomers — the natural L-form and the synthetic mirror-image D-form — and these have entirely different mechanisms of action. The commercial supplement landscape includes three distinct products that are not interchangeable.
- L-phenylalanine (LPA) — the form found in food protein. Enters the catecholamine cascade as described above. The relevant mechanism for mood is increased dopamine and norepinephrine synthesis. Typical doses are 500 to 1,500 mg per day on an empty stomach.
- D-phenylalanine (DPA) — the synthetic enantiomer. Does not enter the catecholamine pathway in any meaningful way because the human body's enzymes are stereospecific for L-amino acids. Its mechanism is inhibition of enkephalinase (a peptidase that degrades the endogenous opioid pentapeptides met-enkephalin and leu-enkephalin), which prolongs endogenous opioid signaling. The clinical effect on mood is primarily through the well-documented affective contribution of endogenous opioid tone — reduced anhedonia, reduced sense of emotional pain, modest mood elevation.
- DL-phenylalanine (DLPA) — a 1:1 racemic mixture of both enantiomers. Acts simultaneously through both mechanisms: catecholamine precursor and enkephalinase inhibitor. Most antidepressant research has used DLPA because the combined mechanism produces a more reliable mood response than either enantiomer alone. Typical doses are 750 to 3,000 mg per day in divided doses.
The clinical question for any individual patient is which mechanism is most relevant. A patient with classic anhedonic depression (low motivation, blunted reward response, fatigue, lack of pleasure) tends to respond to the L-form catecholamine effect. A patient with prominent emotional pain, grief, or "psychic pain" tends to respond more to the D-form enkephalinase effect. For a patient with both presentations, DLPA is the form that carries both mechanisms. There is no laboratory test that reliably predicts which mechanism will dominate — practitioners describe a trial of the supplement itself as the only test.
The First Open Studies (1975, 1977)
An early report of phenylalanine as an antidepressant was a short preliminary note by Fischer, Heller and colleagues, published in 1975 in Arzneimittelforschung. They gave DL- or D-phenylalanine by mouth, 50 or 100 mg a day for 15 days, to 23 people with endogenous depression whose earlier treatment with standard antidepressants (imipramine-type drugs or monoamine oxidase inhibitors) had not worked. A second open study, by Beckmann, Strauss and Ludolph in 1977 in the Journal of Neural Transmission, gave DL-phenylalanine 75 to 200 mg a day to 20 depressed patients for 20 days.
The results reported:
- Fischer 1975: complete euthymia (a return to normal mood) in 17 of 23 patients, reached between day 1 and day 13 of treatment
- Fischer 1975: no important adverse reaction
- Beckmann 1977: 12 of 20 patients (8 with a complete and 4 with a good response) could be discharged without any further treatment; 4 patients with partly untypical depressions had mild to moderate responses, and 4 did not respond at all
- Beckmann 1977: the core symptoms — depressed mood, slowed movement and thinking (retardation) and agitation — improved most; anxiety and sleep problems improved moderately; hypochondriasis and compulsiveness did not change
Both studies were open-label with no placebo group, so their response rates are almost certainly inflated by placebo effect, regression to the mean, and observer bias. Beckmann's group concluded that DL-phenylalanine "might have substantial antidepressant properties" and that more controlled investigations were warranted. Nonetheless, these studies reported that phenylalanine was well tolerated at the doses used, that responses came within about two weeks, and that the core symptoms of depression changed most. The later controlled trials described below give a mixed picture: in a double-blind trial, DL-phenylalanine and imipramine did not differ on depression scores (Beckmann 1979), while a double-blind, placebo-controlled trial of the next precursor in the pathway, tyrosine, found no antidepressant effect (Gelenberg 1990).
The Sabelli Trials (1986, 1996)
Sabelli and colleagues at Rush University in Chicago published a series of open studies in the 1980s and 1990s on phenylalanine and related compounds in depression. Sabelli's theoretical framework was that the related compound phenylethylamine (PEA) — a trace amine derived from phenylalanine via decarboxylation — is itself the active mood-elevating molecule, and that phenylalanine works partly through PEA in addition to catecholamine synthesis.
The 1986 study (Sabelli and colleagues, Journal of Clinical Psychiatry) first measured phenylacetic acid, the main breakdown product of PEA. In the blood it averaged 300.3 ng/ml in 23 drug-free patients with major depression against 491.8 ng/ml in 12 healthy volunteers; in 24-hour urine it averaged 78.2 mg in 144 patients with major depression against 141.1 mg in 48 healthy volunteers. The authors read low phenylacetic acid as a possible marker of the depressed state. In the same paper, L-phenylalanine given on its own, without selegiline, elevated mood in 31 of 40 depressed patients.
A separate open study by Birkmayer, Riederer, Linauer and Knoll (1984, Journal of Neural Transmission) combined L-phenylalanine 250 mg a day with selegiline (L-deprenyl, a selective MAO-B inhibitor that slows PEA breakdown) 5 to 10 mg a day, by mouth or by vein, in 155 patients with unipolar depression. It reported benefit in 90 percent of outpatients and 80.5 percent of inpatients, and its authors credited the effect to phenylethylamine building up in the brain. The 1996 Sabelli follow-up gave PEA itself (10 to 60 mg a day by mouth, with selegiline 10 mg a day to prevent its rapid breakdown). Of 14 patients with major depression who had responded, 12 were still well when re-examined 20 to 50 weeks later; the effective dose did not change and no side effects were apparent. The 1996 paper puts PEA's earlier response rate at 60 percent of depressed patients.
None of these studies was blinded or had a placebo group. In the selegiline studies the amino acid or PEA was always given together with the MAO-B inhibitor, so the contribution of the precursor cannot be separated from the MAO-B inhibition. The combined regimen is also not without risk — selegiline at the doses used in these studies is below the threshold for tyramine reactions, but combining monoamine oxidase inhibitor (MAOI) activity with a catecholamine precursor pushes the catecholaminergic system harder than either alone (see the MAO inhibitor entry under Cautions below).
The Sabelli and Birkmayer authors read their results as support for the PEA hypothesis: that phenylalanine works through PEA as well as the catecholamines, and that slowing their breakdown strengthens the effect. In naturopathic practice, ensuring adequate cofactors (B6, vitamin C, iron, copper, folate, BH4 support via methylated B vitamins) is described as a partial way to approximate this without a prescription MAO-B inhibitor, on the reasoning that the synthesized catecholamines are then stored and released appropriately rather than being immediately degraded.
Beckmann and the European Trials
The German psychiatrist Helmfried Beckmann and colleagues followed their 1977 open study (described above) with a double-blind trial comparing phenylalanine to a standard antidepressant. The 1979 Beckmann trial gave DL-phenylalanine or imipramine, each 150 to 200 mg per day, to 40 depressed patients (20 in each group) for 30 days; 27 patients (14 on imipramine, 13 on phenylalanine) completed the trial. Scores on the Hamilton Depression Rating Scale and on a self-rating questionnaire showed no statistical difference between the two groups. Anxiety ratings were lower with imipramine on days 10 and 20 (but not day 30), and sleep problems improved more with imipramine on days 1, 5 and 10 (but not days 20 and 30). The authors concluded that DL-phenylalanine "might have substantial antidepressant properties", while noting that methodological considerations called for careful interpretation.
A 1980 report by Mann and colleagues in the American Journal of Psychiatry examined D-phenylalanine in endogenous depression (PubMed carries no abstract for it).
These early trials are small by modern standards (20 to 40 patients each), mostly open-label — only the 1979 Beckmann trial was double-blind — and used assessment instruments that have been superseded. They would not be considered adequate evidence for U.S. Food and Drug Administration (FDA) registration today. But the open studies reported most patients improving (17 of 23 in Fischer 1975; 12 of 20 discharged in Beckmann 1977) with few side effects, the same general signal Sabelli described, and they collectively form the historical evidence base for the continued naturopathic use of phenylalanine in depression.
Phenylalanine vs Tyrosine for Depression
An obvious question is whether phenylalanine offers any advantage over tyrosine, which is one step closer to the active catecholamines. Tyrosine bypasses the phenylalanine hydroxylase step entirely and can therefore deliver more substrate to tyrosine hydroxylase per gram of supplement.
The case for tyrosine over phenylalanine:
- One step closer to active product — tyrosine does not need to be hydroxylated before entering the catecholamine cascade, which means it bypasses the BH4-dependent phenylalanine hydroxylase step
- Safe in PKU — tyrosine supplementation does not raise phenylalanine levels and is in fact a standard component of medical foods for PKU patients
- Acute cognitive evidence is stronger — the cleanest randomized controlled trials of catecholamine precursor loading for acute cognitive performance under stress have used tyrosine, not phenylalanine
The case for phenylalanine over tyrosine (or for DLPA in particular):
- Phenylalanine yields PEA in addition to catecholamines — the Sabelli framework argues that phenylethylamine production is part of the mood-elevating effect, and tyrosine does not generate PEA
- DLPA adds the D-form enkephalinase inhibition — the analgesic and emotional-pain effects of the D-form are unique to phenylalanine
- Historical antidepressant trials used phenylalanine — the Fischer and Heller, Beckmann, Sabelli, Birkmayer, and Mann studies all used phenylalanine, so the clinical evidence base is biased toward phenylalanine even if tyrosine might theoretically be equivalent
The one double-blind, placebo-controlled trial of a catecholamine precursor for depression cited on this page tested tyrosine. Gelenberg and colleagues (1990) gave 65 outpatients with major depression L-tyrosine 100 mg per kg of body weight a day, imipramine 2.5 mg per kg a day, or a placebo for 4 weeks. Tyrosine raised, and imipramine lowered, the urine level of MHPG (3-methoxy-4-hydroxyphenylglycol, a breakdown product of noradrenaline), but the authors found no evidence that tyrosine had antidepressant activity. Neither MHPG nor blood amino acid levels predicted or tracked who improved.
How the two line up in practice: for an adult with classic anhedonic depression, no significant pain, no monoamine oxidase inhibitor history, normal BH4 status, and no PKU, the precursor rationale applies equally to L-tyrosine and L-phenylalanine. For people with prominent emotional pain or chronic physical pain in addition to depression, DLPA is the form that adds the D-form enkephalinase inhibition. Practitioners describe moving from L-tyrosine to L-phenylalanine when tyrosine has not helped, on the reasoning that phenylalanine adds PEA. See our Tyrosine page for the parallel discussion from the tyrosine direction.
The Enkephalin / Endorphin Contribution to Mood
The contribution of the endogenous opioid system to mood is underappreciated in mainstream psychiatry. Most depression research and most antidepressant pharmacology has focused on monoamines, with relatively less attention to the enkephalins and endorphins. The clinical reality is that the endogenous opioid system contributes meaningfully to baseline affect, reward, social connection, and the experience of physical and emotional pain.
The D-form of phenylalanine inhibits enkephalinase (also called endopeptidase 24.11 or membrane metalloendopeptidase), which is the principal enzyme responsible for degrading the pentapeptide enkephalins met-enkephalin and leu-enkephalin. By prolonging enkephalin half-life at the synapse, D-phenylalanine effectively amplifies endogenous opioid signaling at the delta and mu opioid receptors.
The mood-relevant consequences include:
- Reduced perception of emotional pain and grief
- Modest mood elevation through increased delta-opioid signaling in the nucleus accumbens and ventral tegmental area
- Reduced anxiety, particularly anxiety with somatic features
- Improved sleep quality in patients whose insomnia is driven partly by pain
- Reduction in the "psychic pain" component that is a frequent feature of severe depression
This is mechanistically distinct from the analgesic effect, although the two often co-occur. A patient with chronic pain plus depression often has both physical pain relief and mood improvement from DLPA, and the mood effect is partly mediated by the pain relief itself and partly by the direct opioid effect on affective circuits.
Importantly, the endogenous opioid pathway tonic activation produced by D-phenylalanine is not associated with tolerance, dependence, or addiction in the way that exogenous opioid drugs are. The mechanism is preservation of physiologic opioid signaling rather than agonism at the receptor, and the effect ceiling is set by the body's own enkephalin production.
Dosing, Timing, and Cofactors
The amounts below are those commonly described in supplement practice; they are not taken from the trials above, which used 50 to 200 mg a day of DL- or D-phenylalanine (Fischer 1975, Beckmann 1977 and 1979) or 250 mg a day of L-phenylalanine with selegiline (Birkmayer 1984).
For L-phenylalanine for mood support:
- Starting dose: 500 mg once daily, in the morning, 30 minutes before breakfast on an empty stomach
- Maintenance: 500 to 1,500 mg per day, divided morning and early afternoon
- Upper end described for use without medical supervision: 2,000 mg per day
- Evening doses are described as disrupting sleep — increased catecholamine production is stimulating
For DLPA (DL-phenylalanine) for combined mood and pain:
- Starting dose: 375 mg twice daily before meals
- Maintenance: 750 to 1,500 mg per day, divided two or three times
- Upper end described: 3,000 mg per day, for short-term use under supervision
- Time described for the full mood and pain effect: 2 to 4 weeks — the enkephalin tone builds gradually
Cofactors that practitioners say determine whether the supplement works (amounts as commonly described):
- Vitamin B6 (pyridoxal-5-phosphate, 25 to 50 mg per day) — required for the L-DOPA to dopamine step
- Vitamin C (500 to 1,000 mg per day) — required for the dopamine to norepinephrine step
- Iron (if ferritin is below 50 ng/mL) — required at the tyrosine hydroxylase active site
- Copper (typically adequate from diet; deficiency primarily seen with excess zinc) — required for dopamine beta-hydroxylase
- Folate and methylated B12 — required for the 5-methyltetrahydrofolate (5-MTHF) and tetrahydrobiopterin (BH4) recycling pathways that supports phenylalanine hydroxylase and tyrosine hydroxylase
- Magnesium — supports multiple steps and the broader stress-response axis
Phenylalanine is usually described as taken away from meals because large neutral amino acids (leucine, isoleucine, valine, tryptophan, methionine) compete with phenylalanine for the LAT1 transporter at the blood-brain barrier. Taking the supplement with a protein meal reduces brain uptake substantially.
Cautions and Contraindications (Including PKU)
- Phenylketonuria (PKU) — absolute contraindication. Patients with classical PKU lack functional phenylalanine hydroxylase. Any supplemental phenylalanine, including from aspartame in diet sodas and sugar-free gum, will accumulate in the brain and cause neurotoxicity. In PKU, every form of supplemental phenylalanine adds to this build-up, without exception: L-, D-, and DL- forms alike.
- MAO inhibitors — serious interaction. Combining phenylalanine with any monoamine oxidase inhibitor (selegiline at depression doses, phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) risks hypertensive crisis. The selegiline studies described above used carefully titrated selegiline under monitoring; outside that monitored setting the combination carries the hypertensive-crisis risk.
- Uncontrolled hypertension. Catecholamine precursor loading can raise blood pressure modestly. The concern is greatest for people whose high blood pressure is not controlled; practitioners describe checking blood pressure weekly while the dose is being raised.
- Levodopa for Parkinson disease. Phenylalanine competes with levodopa for both LAT1 transport and aromatic L-amino acid decarboxylase. Through this competition, phenylalanine can lower the amount of levodopa that reaches the brain.
- Schizophrenia and psychotic spectrum disorders. Increasing dopamine synthesis can worsen positive psychotic symptoms. The concern applies to people with schizophrenia or schizoaffective disorder.
- Pregnancy. Insufficient safety data for high-dose supplementation during pregnancy; dietary protein is the usual source of phenylalanine.
- Migraine. A subset of migraine sufferers report that catecholamine precursor loading triggers migraine, presumably through tyramine-like mechanisms. The reported sign is an increase in migraine frequency.
- Tardive dyskinesia. Long-term high-dose phenylalanine has been associated with rare cases of tardive dyskinesia in older patients with prior dopamine-receptor sensitization. The reports concern older patients who had taken antipsychotic drugs.
Who Tends to Respond Best
Practitioners describe a specific patient phenotype as most likely to benefit from phenylalanine for depression:
- Anhedonic depression — the patient who feels nothing rather than feels bad. The dopamine-deficit profile, with low motivation, blunted reward, fatigue, anhedonia, lack of "drive"
- Atypical depression with hypersomnia and lethargy — rather than melancholic depression with insomnia and agitation
- Depression with prominent fatigue — the catecholamine boost addresses the energy component
- Depression co-occurring with chronic pain — DLPA is the form described for this because of the D-enantiomer enkephalinase mechanism
- Mild to moderate depression — rather than severe depression with suicidality, where prompt psychiatric intervention takes priority
- Treatment-resistant or partial-response patients — phenylalanine can be added to an existing antidepressant regimen (with the exception of monoamine oxidase inhibitors) as an adjunct without dose-altering the existing medication
Patients less likely to respond:
- Melancholic depression with prominent insomnia, anxiety, and agitation — the catecholamine boost can worsen this profile
- Anxious depression where the primary symptom is anxiety rather than low mood — tryptophan and 5-HTP act on the serotonin pathway instead
- Patients with documented methylenetetrahydrofolate reductase-related BH4 deficiency without supportive methylated B vitamins — the synthesis pathway cannot function without BH4
- Patients on antipsychotics — the dopamine-receptor blockade prevents the catecholamine boost from translating into mood effect
For more on the broader serotonin-pathway alternative to the catecholamine pathway for mood, see our Tryptophan page. For the dopamine-deficit profile specifically, see Depression and the related discussion of Tyrosine.
Key Research Papers
- Beckmann H, Strauss MA, Ludolph E (1977). Dl-phenylalanine in depressed patients: an open study. Journal of Neural Transmission. — PubMed PMID: 335027
- Sabelli HC et al. (1986). Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. Journal of Clinical Psychiatry. — PubMed PMID: 3944066
- Sabelli H et al. (1996). Sustained antidepressant effect of PEA replacement. Journal of Neuropsychiatry and Clinical Neurosciences. — PubMed PMID: 9081552
- Beckmann H et al. (1979). DL-phenylalanine versus imipramine: a double-blind controlled study. Archiv für Psychiatrie und Nervenkrankheiten. — PubMed PMID: 387000
- Mann J et al. (1980). D-phenylalanine in endogenous depression. American Journal of Psychiatry. — PubMed PMID: 7435725
- Wood DR et al. (1985). Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Research. — PubMed PMID: 3903813
- Fischer E et al. (1975). Therapy of depression by phenylalanine. Preliminary note. Arzneimittelforschung. — PubMed PMID: 1173765
- Gelenberg AJ et al. (1990). Tyrosine for depression: A double-blind trial. Journal of Affective Disorders. — PubMed PMID: 2142699
- Birkmayer W et al. (1984). L-deprenyl plus L-phenylalanine in the treatment of depression. Journal of Neural Transmission. — PubMed PMID: 6425455
- van Praag HM (1982). Serotonin precursors in the treatment of depression. Advances in Biochemical Psychopharmacology. — PubMed PMID: 6753514
- Kaufmann H et al. (2003). Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. — PubMed PMID: 12885750
- Russo S et al. (2003). Tryptophan as a link between psychopathology and somatic states. Psychosomatic Medicine. — PubMed PMID: 12883120
PubMed Topic Searches
Connections
- All Amino Acids
- Phenylalanine Overview
- Phenylalanine Benefits Hub
- Phenylalanine for Pain Management
- Phenylalanine for Cognitive Function
- Phenylalanine for Skin Pigmentation
- Tyrosine (One Step Closer to Dopamine)
- Tryptophan (Serotonin Precursor)
- Depression
- Vitamin B6 (PLP Cofactor)
- Vitamin C (DBH Cofactor)
- Iron (Tyrosine Hydroxylase)
- Copper (DBH Cofactor)
- Magnesium
- Aspartame (PKU Warning)
- History
- Sources